AstraZeneca said the job cuts are a result of increased efficiencies following a multimillion-dollar upgrade at its plant in Macclesfield. Now, fewer employees are needed to maintain operations.
GMB Union, a local union representing the U.K. workers, called the decision a “hammer blow for manufacturing,” according to the report.
The campus in the U.K. where the job cuts will occur produces small-molecule drugs.
More articles on pharmacy:
10 hospitals seeking pharmacy leadership
Patent protection clause is latest stumbling block for revised NAFTA
Dr. Reddy’s legal win expected to lower cost of opioid addiction treatment
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.